Anti-tumor effect of statin on pancreatic adenocarcinoma: From concept to precision medicine

paythelady.612 shared this article with you from Inoreader Anti-tumor effect of statin on pancreatic adenocarcinoma: From concept to precision medicine Μέσω pubmed: "world j clin cases"... World J Clin Cases. 2021 Jun 26;9(18):4500-4505. doi: 10.12998/wjcc.v9.i18.4500. ABSTRACT A statin is a cholesterol-lowering agent, which inhibits HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase and subsequently reduces the cholesterol precursor, and was first used commercially in 1987. The concept of cholesterol restriction leading to cancer cell dysfunction was proposed in 1992. The interruption of different signaling pathways has been proved in preclinical experiments to elucidate the anti-tumor mechanism of statins in pancreatic adenocarcinoma. Observational studies have shown that the clinical use of statins is beneficial in patients with pancreatic adenocarcinoma, including a chemoprevention effect, post-surgical resection follow-up and therapeutic prognosis of advanced cancer stage. Arrest of the cancer cell cycle by the combined use of gemcitabine and statin was observed in a cell line study. The effect of microbiota on the tumor microenvironment of pancreatic adenocarcinoma is a new therapeutic approach as statins can modulate the gut microbiota. Hence, further randomized trials of statins in pancreatic adenocarcinoma treatment will be warranted with application of precision medicine from microbiota-derived, cell cycle-based and signaling pathway-targeted research. PMID:34222418 | PMC:PMC8223840 | DOI:10.12998/wjcc.v9.i18.4500 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.